Abpro Stock (NASDAQ:ABP)


Chart

Previous Close

$5.80

52W Range

$4.56 - $153.90

50D Avg

$6.04

200D Avg

$7.82

Market Cap

$11.73M

Avg Vol (3M)

$160.30K

Beta

-0.02

Div Yield

-

ABP Company Profile


Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

Mar 09, 2022

Website

ABP Performance


Peer Comparison


TickerCompany
APMAptorum Group Limited
MRKRMarker Therapeutics, Inc.
SNSESensei Biotherapeutics, Inc.
BOLTBolt Biotherapeutics, Inc.
EVGNEvogene Ltd.
LYRALyra Therapeutics, Inc.
MBIOMustang Bio, Inc.
CINGCingulate Inc.
CLRBCellectar Biosciences, Inc.